BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 5046478)

  • 1. Modification by drugs of urinary fibrin/fibrinogen degradation products in glomerulonephritis.
    Clarkson AR; MacDonald MK; Cash JD; Robson JS
    Br Med J; 1972 Jul; 3(5821):255-60. PubMed ID: 5046478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary fibrinogen derivative excretion and intraglomerular fibrin deposition in glomerulonephritis.
    Naish P; Evans DJ; Peters DK
    Br Med J; 1974 Mar; 1(5907):544-6. PubMed ID: 4593708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Origin of urinary fibrin/fibrinogen degradation products in glomerulonephritis.
    Ekberg M; Pandolfi M
    Br Med J; 1975 Apr; 2(5961):17-9. PubMed ID: 48398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum and urinary fibrin-fibrinogen degradation products in glomerulonephritis.
    Clarkson AR; MacDonald MK; Petrie JJ; Cash JD; Robson JS
    Br Med J; 1971 Aug; 3(5772):447-51. PubMed ID: 5567767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary excretion of fibrinogen-fibrin-related antigen in glomerulonephritis: effect of indomethacin.
    Dotremont G; Vermylen J; Donati MB; Van Damme B; Michielsen P
    Perspect Nephrol Hypertens; 1973; 1 Pt 2(0):829-44. PubMed ID: 4803317
    [No Abstract]   [Full Text] [Related]  

  • 6. Urinary excretion of fibrinogen-related materials, complement, and immunoglobulins in proliferative glomerulonephritis and after renal transplantation.
    Hoq MS; Anderton JL; Cunningham M; Cash JD
    Br Med J; 1974 Jun; 2(5918):535-8. PubMed ID: 4209872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Indomethacin and platelet aggregation in chronic glomerulonephritis: existence of non-responders.
    De Gaetano G; Vermylen J; Donati MB; Dotremont G; Michielsen P
    Br Med J; 1974 May; 2(5914):301-3. PubMed ID: 4827105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary fibrin-fibrinogen degradation products (FDP) and glomerulonephritis.
    Hedner U; Ekberg M; Nilsson IM
    Acta Med Scand; 1974; 195(1-2):81-5. PubMed ID: 4817097
    [No Abstract]   [Full Text] [Related]  

  • 9. Characterization and significance of urinary fibrin degradation products.
    Cortes P; Potter EV; Kwaan HC
    J Lab Clin Med; 1973 Sep; 82(3):377-89. PubMed ID: 4199524
    [No Abstract]   [Full Text] [Related]  

  • 10. Urinary excretion of heterophile (sheep) haemagglutinins and fibrin-fibrinogen degradation products after renal transplantation and in proliferative glomerulonephritis.
    Hoq MS; Clarkson AR; Anderton JL; Cash JD
    Lancet; 1973 May; 1(7811):1029-31. PubMed ID: 4122111
    [No Abstract]   [Full Text] [Related]  

  • 11. Urinary fibrin-fibrinogen degradation products and intraglomerular fibrin-fibrinogen deposition in various renal diseases.
    Kamitsuji H; Tani K; Taniguchi A; Masuyama H; Iida Y; Fukui H
    Thromb Res; 1981 Feb; 21(3):285-94. PubMed ID: 7245140
    [No Abstract]   [Full Text] [Related]  

  • 12. Urinary fibrin-fibrinogen degradation products in nephrotic syndrome.
    Hall CL; Pejhan N; Terry JM; Blainey JD
    Br Med J; 1975 Feb; 1(5955):419-22. PubMed ID: 803853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Intraglomerular coagulation and fibrinolysis in human primary glomerular diseases].
    Shibata K; Dohi K; Fujii Y; Ishikawa H
    Nihon Jinzo Gakkai Shi; 1991 Aug; 33(8):719-29. PubMed ID: 1770632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urinary FDP, heterophile agglutinins IgG, IgM, and C3 in renal homotransplant rejection and glomerulonephritis.
    Anderton JL; Hoq MS; Clarkson AR; Cash JD
    Proc Eur Dial Transplant Assoc; 1973; 10(0):500-7. PubMed ID: 4607330
    [No Abstract]   [Full Text] [Related]  

  • 15. Urinary fibrin-fibrinogen degradation products (FDP) in renal diseases and during thrombolytic therapy.
    Hedner U
    Scand J Clin Lab Invest; 1973 Oct; 32(2):175-82. PubMed ID: 4588514
    [No Abstract]   [Full Text] [Related]  

  • 16. Fibrin/fibrinogen degradation products in glomerulonephritis.
    Yatzidis H
    Br Med J; 1971 Sep; 3(5777):767. PubMed ID: 5097978
    [No Abstract]   [Full Text] [Related]  

  • 17. Urinary fibrin/fibrinogen degradation products measured using an anti-fibrinogen antibody predict orthostatic proteinuria.
    Kanai H; Sawanobori E; Kobayashi A; Goto M; Higashida K; Sugita K
    Pediatr Int; 2018 Jul; 60(7):639-644. PubMed ID: 29654610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of urinary excretion of fibrin degradation products during treatment of glomerulonephritis.
    Michielsen P; Roels L; Vanrenterghem Y; Boel A; van Damme B; Vermylen J
    Clin Nephrol; 1976 Mar; 5(3):105-13. PubMed ID: 1261101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. F.D.P. in glomerulonephritis.
    Preston FE; Malia RG; Blackburn EK; Platts M
    Br Med J; 1971 Oct; 4(5780):171-2. PubMed ID: 5113031
    [No Abstract]   [Full Text] [Related]  

  • 20. Urinary fibrin-fibrinogen degradation poducts after renal homotransplantation.
    Clarkson AR; Morton JB; Cash JD
    Lancet; 1970 Dec; 2(7685):1220-3. PubMed ID: 4098659
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.